| Anticoagulation after cardioembolic stroke: to bridge or not to bridge? | |
| | |
MedLine Citation:
|
PMID: 18625852 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Most patients with cardioembolic stroke require long-term anticoagulation. Still, uncertainty exists regarding the best mode of starting long-term anticoagulation. Design, Setting, and Patients We conducted a retrospective review of all patients with cardioembolic stroke admitted to our center from April 1, 2004, to June 30, 2006, and not treated with tissue plasminogen activator. Patients were grouped by treatment: no treatment, aspirin only, aspirin followed by warfarin sodium, intravenous heparin sodium in the acute phase followed by warfarin (heparin bridging), and full-dose enoxaparin sodium combined with warfarin (enoxaparin bridging). Outcome measures and adverse events were collected prospectively. Laboratory values were captured from the records. MAIN OUTCOME MEASURES: Symptomatic hemorrhagic transformation, stroke progression, and discharge modified Rankin Scale score. RESULTS: Two hundred four patients were analyzed. Recurrent stroke occurred in 2 patients (1%). Progressive stroke was the most frequent serious adverse event, seen in 11 patients (5%). Hemorrhagic transformation occurred in a bimodal distribution-an early benign hemorrhagic transformation and a late symptomatic hemorrhagic transformation. All of the symptomatic hemorrhagic transformation cases were in the enoxaparin bridging group (10%) (P = .003). Systemic bleeding occurred in 2 patients (1%) and was associated with heparin bridging (P = .04). CONCLUSIONS: Anticoagulation of patients with cardioembolic stroke can be safely started with warfarin shortly after stroke. Heparin bridging and enoxaparin bridging increase the risk for serious bleeding. |
| | |
Authors:
|
Hen Hallevi; Karen C Albright; Sheryl Martin-Schild; Andrew D Barreto; Sean I Savitz; Miguel A Escobar; Nicole R Gonzales; Elizabeth A Noser; Kachi Illoh; James C Grotta |
Publication Detail:
|
Type: Comparative Study; Journal Article Date: 2008-07-14 |
Journal Detail:
|
Title: Archives of neurology Volume: 65 ISSN: 1538-3687 ISO Abbreviation: Arch. Neurol. Publication Date: 2008 Sep |
Date Detail:
|
Created Date: 2008-09-09 Completed Date: 2008-09-29 Revised Date: 2009-11-18 |
Medline Journal Info:
|
Nlm Unique ID: 0372436 Medline TA: Arch Neurol Country: United States |
Other Details:
|
Languages: eng Pagination: 1169-73 Citation Subset: AIM; IM |
Affiliation:
|
Department of Neurology, University of Texas Health Science Center at Houston, 6431 Fannin St, MSB 7.044, Houston, TX 77030, USA. hen.hallevi@uth.tmc.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Aged, 80 and over Anticoagulants / administration & dosage*, adverse effects Atrial Fibrillation / chemically induced, pathology Embolism / complications, drug therapy*, pathology Female Heart Diseases / complications, drug therapy*, pathology Humans Male Middle Aged Prospective Studies Recurrence Retrospective Studies Stroke / complications, drug therapy*, pathology Time Factors |
| Grant Support | |
ID/Acronym/Agency:
|
P50 NS044227-019002/NS/NINDS NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Anticoagulants |
| Comments/Corrections | |
Comment In:
|
Arch Neurol. 2008 Sep;65(9):1157
[PMID:
18779416
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Nav1.4 deregulation in dystrophic skeletal muscle leads to Na+ overload and enhanced cell death.
Next Document: Molecular predictors in glioblastoma: toward personalized therapy.